体外研究
MBC-11 shows similar activity profiles and significantly inhibits growth of all three cell lines between 10
-8
and 10
-4
M. MBC-11 decreases KAS-6/1 cell growth from approximately 56% at 10
-8
M to 6% at 10
-5
M.
Cell Proliferation Assay
Cell Line:
Human multiple myeloma cell lines (KAS-6/1, DP-6, KP-6).
Concentration:
Between 10
-8
and 10
-4
M.
Incubation Time:
48 hours.
Result:
Significantly inhibited multiple myeloma cell proliferation of each cell line at the majority of the tested concentrations.
体内研究
MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%). MBC-11 also significantly decreases bone tumor burden compared to PBS- or zoledronate-treated mice.
Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group.
These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD).
Animal Model:
Approximately four-week old female Balb/c mice inoculated (s.c. injection into their mammary fatpads) with 500,000 4T1/luc cells at day 0 (breast tumor model).
Dosage:
0.04, 0.4, or 4.0 μg/day.
Administration:
S.C. daily from day 7 to 21.
Result:
The dose of 0.04 μg/day had a lower incidence of bone metastases compared to those treated with PBS or 0.04 μg/day zoledronate.
Animal Model:
Female Balb/c and SCID mice (four-six weeks old).
Dosage:
500, 100, 1, or 0.01 μg/100 μL.
Administration:
S.C. daily for 24 or 49 days.
Result:
Weight gained in MBC-11 treated mice with different doses was similar to the PBS treated group.
